Overview

• U.S. insulin pump maker's Q1 revenue rose 34%, beating analyst expectations

• Adjusted EPS for Q1 beat analyst expectations

• Company raised full-year revenue growth outlook after strong Q1 demand

Outlook

• Insulet raises full-year total company revenue growth outlook to 21% - 23%

• Company expects adjusted EPS growth above 25% for full-year 2026

• Insulet sees FY 2026 adjusted operating margin expanding by about 100 bps year-over-year

Result Drivers

• OMNIPOD GROWTH - Revenue growth driven by strong demand for Omnipod products, with total Omnipod revenue up 37% and international Omnipod revenue up 59% (45% in constant currency)

• PRODUCT LAUNCHES & INNOVATION - Recent launches of Omnipod 5 and Omnipod Discover in new markets, and algorithm updates, contributed to growth and expanded market reach

• OPERATING MARGIN EXPANSION - Company reported operating margin expansion, citing execution on strategic priorities and scaling global operations

Company press release: ID:nBwkqdcGa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

• Wall Street's median 12-month price target for Insulet Corp is $350.00, about 108.9% above its May 5 closing price of $167.53

• The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 41 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.